Kite, a Gilead Company , and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which ...
A new study by Phoenix's Barrow Neurological Institute and the University of Calgary has found which injectable treatments showed the most benefit for migraine patients and should be routinely offered ...